Short-Term and Late-Term Effects of Psilocybin on Symptoms in Major Depression
JAMA Network Open May 15, 2026 Hampus Yngwe, Pontus Plavén-sigray, Carl Johan Ekman et al. 1 citation
Importance: Psilocybin has been proposed as a rapid-acting antidepressant (onset 6 weeks), but evidence from randomized clinical trials remains limited, particularly in the broader major depressive disorder (MDD) population. Objective: To assess short-term and long-term antidepressant effects of psilocybin therapy in patients with MDD. Design, Setting, and Participants: This double-blind,...